Study Evaluating Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.

This study has been completed.
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00227214
First received: September 12, 2005
Last updated: June 24, 2010
Last verified: June 2010
  Purpose

The aim of this study is to determine the prevalence of pneumococcal meningitis in the paediatric population in Spain four years after the marketing of Prevenar. Also secondary objectives are: 1) to determine the clinical characteristics and outcome of the disease; and 2) to determine serotypes and antibiotic resistance patterns.


Condition
Pneumococcal Meningitis

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Prevalence of Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.

Resource links provided by NLM:


Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Enrollment: 160
Study Start Date: January 2004
Study Completion Date: December 2006
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   up to 14 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Children from 0 up to 14 years of age with a diagnosis of confirmed or probable pneumococcal meningitis or with a diagnosis of suspected bacterial meningitis without bacterial or viral isolation.

Criteria

Inclusion Criteria:

  • All children from 0 up to 14 years with diagnosis of confirmed or probable pneumococcal meningitis or with diagnosis of suspected bacterial meningitis without bacterial or viral isolation will be included into the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00227214

Locations
Spain
Alcalá de Henares, Spain
Alcorcón, Spain
Badalona, Spain
Barakaldo, Spain
Barcelona, Spain
Barco de Valdeorras, Spain
Bilbao, Spain
Boadilla del Monte, Spain
CEE, Spain
Esplugues de Llobregat, Spain
Estella, Spain
Ferrol, Spain
Figueres, Spain
Getafe, Spain
Girona, Spain
Granollers, Spain
La Coruña, Spain
Leganés, Spain
Lleida, Spain
Lugo, Spain
Madrid, Spain
Mondragón, Spain
Monforte de Lemos, Spain
Móstoles, Spain
Ourense, Spain
Pamplona, Spain
Pontevedra, Spain
Reus, Spain
Ribeira, Spain
Sabadell, Spain
San Lorenzo de El Escorial, Spain
San Sebastián, Spain
Tarragona, Spain
Terrasa, Spain
Tudela, Spain
Verín, Spain
Vigo, Spain
Vitoria, Spain
Zumárraga, Spain
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00227214     History of Changes
Other Study ID Numbers: 0887X-101539
Study First Received: September 12, 2005
Last Updated: June 24, 2010
Health Authority: Spain: Spanish Agency of Medicines

Additional relevant MeSH terms:
Meningitis
Meningitis, Pneumococcal
Central Nervous System Infections
Central Nervous System Diseases
Nervous System Diseases
Meningitis, Bacterial
Central Nervous System Bacterial Infections
Bacterial Infections
Pneumococcal Infections
Streptococcal Infections
Gram-Positive Bacterial Infections

ClinicalTrials.gov processed this record on September 18, 2014